Your browser is no longer supported. Please, upgrade your browser.
Oyster Point Pharma, Inc.
Index- P/E- EPS (ttm)-3.11 Insider Own1.10% Shs Outstand26.04M Perf Week-0.54%
Market Cap325.15M Forward P/E- EPS next Y-5.24 Insider Trans-85.69% Shs Float24.36M Perf Month-16.53%
Income-80.80M PEG- EPS next Q-1.38 Inst Own90.50% Short Float10.23% Perf Quarter6.74%
Sales17.90M P/S18.16 EPS this Y-36.60% Inst Trans5.26% Short Ratio9.57 Perf Half Y-20.42%
Book/sh5.28 P/B2.46 EPS next Y-36.80% ROA-43.70% Target Price50.25 Perf Year-35.04%
Cash/sh7.35 P/C1.77 EPS next 5Y- ROE-50.00% 52W Range9.86 - 25.89 Perf YTD-28.92%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-49.86% Beta-
Dividend %- Quick Ratio12.50 Sales past 5Y- Gross Margin- 52W Low31.64% ATR1.07
Employees62 Current Ratio12.50 Sales Q/Q- Oper. Margin- RSI (14)39.49 Volatility6.25% 7.52%
OptionableYes Debt/Eq0.30 EPS Q/Q-7.40% Profit Margin- Rel Volume0.93 Prev Close12.93
ShortableYes LT Debt/Eq0.30 EarningsNov 04 AMC Payout- Avg Volume260.27K Price12.98
Recom2.20 SMA20-18.53% SMA50-3.91% SMA200-15.03% Volume242,838 Change0.39%
Nov-09-21Downgrade JP Morgan Overweight → Neutral $30 → $23
Nov-25-19Initiated Piper Jaffray Overweight $35
Nov-25-19Initiated JP Morgan Overweight $26
Nov-25-19Initiated Cowen Outperform $40
Jan-19-22 09:38PM  
Jan-04-22 05:08PM  
Dec-24-21 09:00AM  
Dec-21-21 04:05PM  
Dec-15-21 09:26AM  
Nov-30-21 07:09PM  
Nov-24-21 07:00AM  
Nov-15-21 07:00AM  
Nov-09-21 07:01AM  
Nov-06-21 01:31AM  
Nov-04-21 04:05PM  
Nov-03-21 04:05PM  
Nov-02-21 04:45PM  
Oct-30-21 07:04AM  
Oct-28-21 07:00AM  
Oct-19-21 11:26AM  
Oct-18-21 05:36PM  
Sep-01-21 05:24PM  
Aug-06-21 10:12AM  
Aug-05-21 10:31PM  
Aug-04-21 08:30AM  
Aug-02-21 04:10PM  
Jul-05-21 07:16AM  
Jul-01-21 06:00AM  
Jun-29-21 04:42PM  
Jun-21-21 04:01PM  
Jun-10-21 07:00AM  
Jun-03-21 12:38PM  
May-07-21 09:01AM  
May-06-21 04:01PM  
May-01-21 08:00AM  
Apr-30-21 08:00AM  
Apr-05-21 10:46AM  
Mar-03-21 08:32AM  
Mar-02-21 06:00AM  
Feb-25-21 04:01PM  
Feb-18-21 10:31PM  
Feb-12-21 09:14AM  
Jan-18-21 07:05AM  
Dec-29-20 04:01PM  
Dec-18-20 07:00AM  
Dec-12-20 11:36PM  
Dec-07-20 07:00AM  
Dec-01-20 04:01PM  
Nov-25-20 09:00AM  
Nov-13-20 07:00AM  
Nov-06-20 11:31AM  
Nov-05-20 04:01PM  
Oct-29-20 04:01PM  
Oct-08-20 04:01PM  
Sep-11-20 08:00AM  
Aug-17-20 10:33AM  
Aug-11-20 01:02PM  
Aug-05-20 07:00AM  
Jul-31-20 04:01PM  
Jun-01-20 11:39AM  
May-28-20 09:07AM  
May-24-20 12:25PM  
May-19-20 06:08PM  
May-15-20 02:02AM  
May-12-20 04:20PM  
May-11-20 10:31PM  
May-04-20 04:05PM  
Mar-30-20 07:30AM  
Feb-27-20 04:01PM  
Feb-24-20 08:00AM  
Jan-12-20 08:00PM  
Dec-24-19 07:24AM  
Dec-23-19 09:00AM  
Dec-17-19 08:00AM  
Dec-03-19 03:29PM  
Nov-25-19 08:00AM  
Nov-22-19 05:12PM  
Nov-05-19 09:10AM  
Oct-28-19 08:20AM  
Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that has completed Phase III clinical trial for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratopathy. Oyster Point Pharma, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lochner DanielChief Financial OfficerNov 01Option Exercise11.518,59098,87158,221Nov 02 05:49 PM
Nau JeffreyPresident and CEOOct 21Option Exercise1.0250,00051,000110,898Oct 22 04:41 PM
Versant Venture Capital VI, L.10% OwnerOct 18Sale14.84550,0008,160,7364,987Oct 20 04:38 PM
LINK WILLIAM J PHDDirectorOct 18Sale14.84550,0008,160,7364,987Oct 20 04:32 PM
Ozawa ClareDirectorOct 18Sale14.84550,0008,160,7364,987Oct 20 04:31 PM
Lochner DanielChief Financial OfficerSep 02Option Exercise11.517,50086,32549,631Sep 07 08:03 AM
Nau JeffreyPresident and CEOSep 01Option Exercise1.0210,00010,20060,898Sep 01 06:00 PM
Lochner DanielChief Financial OfficerJul 28Option Exercise11.517,50086,32542,131Jul 29 05:05 PM
Nau JeffreyPresident and CEOApr 02Option Exercise1.0210,00010,20050,898Apr 02 02:11 PM
Lochner DanielChief Financial OfficerFeb 24Option Exercise11.519,109104,84534,631Feb 26 07:50 PM
Nau JeffreyPresident and CEOFeb 19Option Exercise1.0210,00010,20040,898Feb 23 08:13 PM